Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 286

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate

Open access
Seeman, Ego, Delmas, Pierre D, Hanley, David A, Sellmeyer, Deborah, Cheung, Angela M, Shane, Elizabeth, Kearns, Ann, Thomas, Thierry, Boyd, Steven K, Boutroy, Stephanie, Bogado, Cesar, Majumdar, Sharmila, Fan, Michelle, Libanati, Cesar, Zanchetta, Jose·2010·Journal of Bone and Mineral Research

Abstract

The intensity of bone remodeling is a critical determinant of the decay of cortical and trabecular microstructure after menopause. Denosumab suppresses remodeling more than alendronate, leading to greater gains in areal bone mineral density (aBMD). These greater gains may reflect differing effects of each drug on bone microarchitecture and strength. In a phase 2 double-blind pilot study, 247 postmenopausal women were randomized to denosumab (60 mg subcutaneous 6 monthly), alendronate (70 mg oral weekly), or placebo for 12 months. All received daily calcium and vitamin D. Morphologic changes were assessed using high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal radius and distal tibia and QCT at the distal radius. Denosumab decreased serum C-telopeptide more rapidly and markedly than alendronate. In the placebo arm, total, cortical, and trabecular BMD and cortical thickness decreased (−2.1% to −0.8%) at the distal radius after 12 months. Alendronate prevented the decline (−0.6% to 2.4%, p = .051 to <.001 versus placebo), whereas denosumab prevented the decline or improved these variables (0.3% to 3.4%, p < .001 versus placebo). Changes in total and cortical BMD were greater with denosumab than with alendronate (p ≤ .024). Similar changes in these parameters were observed at the tibia. The polar moment of inertia also increased more in the denosumab than alendronate or placebo groups (p < .001). Adverse events did not differ by group. These data suggest that structural decay owing to bone remodeling and progression of bone fragility may be prevented more effectively with denosumab. © 2010 American Society for Bone and Mineral Research

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jbmr.81

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 286

Metadata

Authors
Seeman, E., Delmas, P. D., Hanley, D. A., Sellmeyer, D., Cheung, A. M., Shane, E., Kearns, A., Thomas, T., Boyd, S. K., Boutroy, S., Bogado, C., Majumdar, S., Fan, M., Libanati, C., & Zanchetta, J.
Venue
Journal of Bone and Mineral Research
Published
2010-07-30
Volume
25
Issue
8
Pages
1886-1894
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
OpenAlex
W2115028313
Cited by
286
References
23
FWCI
29.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate. https://app.cochat.ai/papers/10.1002/jbmr.81
The paper
Seeman, E., Delmas, P. D., Hanley, D. A., Sellmeyer, D., Cheung, A. M., Shane, E., Kearns, A., Thomas, T., Boyd, S. K., Boutroy, S., Bogado, C., Majumdar, S., Fan, M., Libanati, C., & Zanchetta, J. (2010). Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.81

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.